In 2025, Embla Medical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).
Embla Medical has also provided a category-level breakdown for 10 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Scope 1 | 2,290a | 2,390a | 2,460b | |
Total Scope 2 | ||||
Market-Based | 170a | 310a | 170b | |
Location-Based | 4,140a | 4,330a | 3,990b | |
Total Scope 3 | 98,380a | 104,390a | 103,870b | |
Total Scope 1 Revenue Intensity (tCO2e/$M) | 0.39a | 0.4422a | 3.131b |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, the total operational greenhouse gas (GHG) emissions of Embla Medical amounted to 6,430 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a
Compared to 2024, the total operational greenhouse gas (GHG) emissions of Embla Medical decreased by 4.32%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a
In 2025, the total Scope 1 emissions of Embla Medical were 2,290 metric tons of CO₂ equivalent (tCO₂e).a
Since 2019, Embla Medical's Scope 1 emissions have decreased by 20.21%, reflecting a declining long-term trend in Scope 1 emissions over time.a
Compared to the previous year (2024), Embla Medical's Scope 1 emissions decreased by 4.18%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.a
In 2025, Embla Medical reported Scope 2 greenhouse gas (GHG) emissions of 170 tCO₂e using the market-based method and 4,140 tCO₂e using the location-based method.a
Since 2019, Embla Medical's Scope 2 greenhouse gas (GHG) emissions (Location-Based) have decreased by 15.34%, reflecting a declining long-term trend in Scope 2 emissions over time.ab
Compared to the previous year (2024), Embla Medical's Scope 2 emissions (Location-Based) have remained relatively stable, indicating that Embla Medical's emissions have plateaued with no significant change in its energy consumption footprint.a
In 2025, Embla Medical reported its Scope 2 emissions using the market-based method and using the location-based method.a
In 2025, Embla Medical reported 98,380 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a
The 2025 disclosure of Embla Medical includes a breakdown across 7 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2024, demonstrating consistent Scope 3 emissions reporting coverage year over year.a
In 2025, Embla Medical reported total Scope 3 emissions of 98,380 metric tons of CO₂ equivalent (tCO₂e).a
Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a
Compared to the previous year (2024), Embla Medical's Scope 3 emissions remained relatively stable, indicating that Embla Medical's emissions have plateaued with no significant change in its value chain footprint.a
In 2025, Embla Medical reported emissions for 7 out of the 15 Scope 3 categories defined by the GHG Protocol.a
This partial disclosure allows for some insight into the company's indirect impacts.
In 2025, the largest contributors to Embla Medical's Scope 3 emissions were:a
In 2025, Embla Medical reported Scope 1 greenhouse gas (GHG) emissions of 2,290 tCO₂e and total revenues of USD 5,872 millions. This translates into an emissions intensity of 0.39 tCO₂e per millions USD.a
In 2025, Embla Medical reported a Scope 1 emissions intensity of 0.39 tCO₂e per millions USD. Compared to the peer group median of 2.51, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a
In 2025, Embla Medical ranked 3 out of 25 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a
This places Embla Medical among the top performers, with one of the lowest emissions intensities relative to peers.a
In 2025, Embla Medical reported a total carbon footprint of 104,810 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 5.67% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a
The largest contributor to Embla Medical's total carbon footprint was Scope 3 emissions, accounting for 93.87% of the company's total carbon footprint, followed by Scope 2 emissions at 3.95%.a